2 superb FTSE 100 stocks I’d buy for a SIPP and hold for a decade

This Fool highlights a pair of excellent blue-chip stocks that he’d buy today and tuck away in a SIPP portfolio for the long run.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

A senior group of friends enjoying rowing on the River Derwent

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Warren Buffett famously said: “If you aren’t thinking about owning a stock for 10 years, don’t even think about owning it for 10 minutes.” A self-invested personal pension (SIPP) is perfect for this mindset.

That’s because it allows me to tax-efficiently save, invest and build up a pot of money for retirement. And that might be a decade or more away.

Here are two quality FTSE 100 stocks I’d buy for a SIPP today.

Should you invest £1,000 in Aviva right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Aviva made the list?

See the 6 stocks

Please note that tax treatment depends on the individual circumstances of each client and may be subject to change in future. The content in this article is provided for information purposes only. It is not intended to be, neither does it constitute, any form of tax advice. Readers are responsible for carrying out their own due diligence and for obtaining professional advice before making any investment decisions.

The biggest fish

To start, I’d go with the UK’s largest company by market capitalisation: AstraZeneca (LSE: AZN). The pharma giant is just ahead of fellow Footsie heavyweight Shell in the rankings.

The stock has more than doubled in five years and nearly trebled over a decade. A combination of smart leadership, shrewd acquisitions and surging top and bottom-line growth have all driven this performance.

Created with Highcharts 11.4.3AstraZeneca Plc PriceZoom1M3M6MYTD1Y5Y10YALL5 Jun 20195 Jun 2024Zoom ▾Jul '19Jan '20Jul '20Jan '21Jul '21Jan '22Jul '22Jan '23Jul '23Jan '2420202020202120212022202220232023202420245k7.5k10k12.5k15kwww.fool.co.uk

In 2014, the drugmaker set a target of reaching more than $45bn in revenue by 2023. Having achieved that, it’s now aiming to grow revenue to $80bn by 2030, which would be a rise of 75%.

It expects to launch 20 new medicines by then, as well as increase sales from its massive existing oncology, biopharmaceuticals, and rare diseases portfolio. And it’s targeting a mid-30% core operating profit margin, up from 28% in 2020.

While I wouldn’t bet against all that happening, the company can be hit by late-stage clinical trial failures. That’s just the nature of the beast here, as are potential litigation and regulation issues.

Nevertheless, AstraZeneca’s driving ambition is to transform oncology by replacing traditional treatments like chemotherapy and radiotherapy with more targeted treatments.

This is a vision I’m invested in myself, having added Astra shares to my portfolio a few months ago.

To my mind, an ageing global population and rising cases of cancer should naturally lead to the company becoming more valuable over time.

The journey won’t always be smooth, but this is a FTSE 100 stock I’d want in my SIPP for the long haul.

A world-class data firm

Next up, we have Experian (LSE: EXPN). This is one of the world’s largest credit reporting agencies. It provides data and analytical tools to lenders around the globe to help them make informed decisions.

Like AstraZeneca, this stock has been performing very strongly. It’s up 26% over the past year, easily outperforming the wider FTSE 100 in the process.

Created with Highcharts 11.4.3Experian Plc PriceZoom1M3M6MYTD1Y5Y10YALL5 Jun 20195 Jun 2024Zoom ▾Jul '19Jan '20Jul '20Jan '21Jul '21Jan '22Jul '22Jan '23Jul '23Jan '242020202020212021202220222023202320242024www.fool.co.uk

There are a few reasons I like Experian. For starters, it boasts strong returns on capital and equity. In its last financial year that ended in March, it achieved a very healthy 17% net profit margin.

Second, the company has credit information on over 1.4bn consumers and 191m businesses around the globe. This is almost impossible to replicate, giving it a powerful and durable competitive advantage.

Third, these high-quality datasets can be used for new analytics tools powered by artificial intelligence.

The one issue I’d highlight here though is valuation, with the stock trading at around 29 times forward earnings. That’s much higher than the FTSE 100 average, which could mean any disappointing results might send the price lower.

However, I don’t think the valuation is outrageous for a world-class data firm. I can see the stock outperforming the UK market over the next decade and plan to add it to my SIPP.

Should you invest £1,000 in Aviva right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets.

And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Aviva made the list?

See the 6 stocks

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Ben McPoland has positions in AstraZeneca Plc. The Motley Fool UK has recommended AstraZeneca Plc and Experian Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

We think earning passive income has never been easier

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

More on Investing Articles

Investing Articles

10% dividend yield! Here’s a FTSE 100 share to consider in April for passive income

This FTSE 100 stock just soared past the 10% yield mark, making it a potentially lucrative option for investors targeting…

Read more »

Young black woman using a mobile phone in a transport facility
Investing Articles

3 FTSE 100 safe haven stocks to consider as trade wars bite

I'm confident in the long-term outlook for the FTSE index of stocks. But these blue chips may protect investors from…

Read more »

Investing Articles

Here’s how Trump tariffs could hand us some top passive income bargains

As tariff terror grips the stock market, it's time for passive income investors to steel our nerves and look for…

Read more »

Investing Articles

These FTSE shares may offer some safety as Trump slaps tariffs on trading partners

FTSE shares moved lower on 3 April, after US President Donald Trump introduced hefty tariffs on its trading partners. These…

Read more »

Investing Articles

6.8% dividend yield! Consider these 2 ‘secret’ passive income stocks to target a £1,360 payday in 2025

Looking for ways to generate above-average dividend income? These lesser-bought income stocks are worth a close look.

Read more »

Elevated view over city of London skyline
Investing Articles

The M&G dividend yields over 10% — and could get higher!

Christopher Ruane explains why he's upbeat about the long-term outlook for the M&G dividend yield and would happily buy the…

Read more »

Young Caucasian man making doubtful face at camera
Investing Articles

2 popular UK growth stocks I wouldn’t touch with a bargepole in today’s market

Buying growth stocks can deliver market-beating returns, but this FTSE 250 pair doesn't look like a convincing investment for our…

Read more »

The flag of the United States of America flying in front of the Capitol building
Investing Articles

10 FTSE shares falling today after President Trump’s tariffs bombshell!

Our writer explains why JD Sports Fashion from the FTSE 100 and a diverse bunch of other UK stocks are…

Read more »